LDL-C significantly reduction from baseline ( 4.18 0.54 ) mmol/L to ( 3.44 0.61 ) mmol/L ( -17.7 % , P < 0.05 ) at week 3 and ( 3.35 0.39 ) mmol/L ( -19.9 % , P < 0.05 ) at week 6 in the treatment group , whereas in placebo group from ( 4.11 0.54 ) mmol/L at baseline to ( 3.47 0.60 ) mmol/L ( -15.57 % , P < 0.05 ) and ( 3.61 0.39 ) mmol/L ( -12.17 % , P < 0.05 ) at week 3 and week 6 , respectively .